Phenytoin (All indications)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9192
R31819
Aydin (Phenytoin) (Controls exposed to Lamotrigine, sick), 2020 Preterm delivery (before 37 weeks of gestation) throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 13.00 [0.10;1680.94] C
excluded (control group)
0/1   0/7 0 1
ref
S9193
R31829
Aydin (Phenytoin) (Controls unexposed, sick), 2020 Preterm delivery (before 37 weeks of gestation) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 7.80 [0.12;487.53] C 0/1   2/22 2 1
ref
S9272
R32150
Bank (Phenytoin) (Mixed indications), 2017 Premature (<37 weeks gestation) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 4.60 [0.15;144.69] C 0/3   1/36 1 3
ref
S9186
R31764
Arkilo (Phenytoin), 2015 Premature delivery during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 0.65 [0.03;14.95] C 0/5   3/24 3 5
ref
S9275
R32162
Kilic (Phenytoin) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.06 [0.06;19.86] C
excluded (control group)
0/5   83/880 83 5
ref
S9276
R32165
Kilic (Phenytoin) (Controls unexposed NOS) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: No 2.10 [0.11;39.05] C
excluded (control group)
0/5   33,974/676,834 33,974 5
ref
S9277
R32168
Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 1.42 [0.08;26.49] C 0/5   383/5,296 383 5
ref
S9187
R31777
Artama (Phenytoin) (Controls exposed to Lamotrigine, sick), 2013 Preterm birth (<37 gestational weeks) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.72 [0.34;8.58] C
excluded (control group)
2/26   8/173 10 26
ref
S9188
R31789
Artama (Phenytoin) (Controls unexposed, disease free), 2013 Preterm birth (<37 gestational weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.85 [0.43;7.88]
excluded (control group)
2/26   30,027/719,509 30,029 26
ref
S9190
R31813
Artama (Phenytoin) (Controls unexposed, sick), 2013 Preterm birth (<37 gestational weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.52 [0.34;6.76] 2/26   85/1,793 87 26
ref
S9216
R31976
Pennell (Phenytoin), 2012 Preterm Birth (< 37 weeks GA) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 1.88 [0.57;6.13] C 6/55   6/98 12 55
ref
S9263
R32124
Koch (Phenytoin), 1996 Prematurity (< 37 weeks) during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: No Matched 11.64 [0.97;139.55] C 2/13   1/65 3 13
ref
Total 7 studies 2.14 [0.99;4.62] 491 108
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Phenytoin) (Controls unexposed, sick), 2020Aydin, 2020 1 7.80[0.12; 487.53]213%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Bank (Phenytoin) (Mixed indications), 2017Bank, 2017 2 4.60[0.15; 144.69]135%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Arkilo (Phenytoin), 2015Arkilo, 2015 3 0.65[0.03; 14.95]356%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014Kilic, 2014 4 1.42[0.08; 26.49]38357%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Artama (Phenytoin) (Controls unexposed, sick), 2013Artama, 2013 5 1.52[0.34; 6.76]872627%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Pennell (Phenytoin), 2012Pennell, 2012 6 1.88[0.57; 6.13]125542%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Koch (Phenytoin), 1996Koch, 1996 7 11.64[0.97; 139.55]31310%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (7 studies) I2 = 0% 2.14[0.99; 4.62]4911080.250.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Phenytoin) (Controls unexposed, sick; 2: Phenytoin) (Mixed indications; 3: Phenytoin; 4: Phenytoin) (Controls unexposed, sick) (Mixed indications; 5: Phenytoin) (Controls unexposed, sick; 6: Phenytoin; 7: Phenytoin;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.14[0.99; 4.62]4911080%NAAydin (Phenytoin) (Controls unexposed, sick), 2020 Bank (Phenytoin) (Mixed indications), 2017 Arkilo (Phenytoin), 2015 Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Phenytoin) (Controls unexposed, sick), 2013 Pennell (Phenytoin), 2012 Koch (Phenytoin), 1996 7 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 11.64[0.97; 139.55]313 -NAKoch (Phenytoin), 1996 1 unexposed, sickunexposed, sick 1.75[0.49; 6.21]472320%NAAydin (Phenytoin) (Controls unexposed, sick), 2020 Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Phenytoin) (Controls unexposed, sick), 2013 3 exposed to other treatment, sickexposed to other treatment, sick 1.81[0.63; 5.20]16630%NABank (Phenytoin) (Mixed indications), 2017 Arkilo (Phenytoin), 2015 Pennell (Phenytoin), 2012 3 Tags Adjustment   - No  - No 2.42[0.98; 5.95]404820%NAAydin (Phenytoin) (Controls unexposed, sick), 2020 Bank (Phenytoin) (Mixed indications), 2017 Arkilo (Phenytoin), 2015 Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 Pennell (Phenytoin), 2012 Koch (Phenytoin), 1996 6   - Yes  - Yes 1.52[0.34; 6.78]8726 -NAArtama (Phenytoin) (Controls unexposed, sick), 2013 1 Controls   - epilepsy indication  - epilepsy indication 1.42[0.08; 26.49]3835 -NAKilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 1 MatchedMatched 11.64[0.97; 139.55]313 -NAKoch (Phenytoin), 1996 1 All studiesAll studies 2.14[0.99; 4.62]4911080%NAAydin (Phenytoin) (Controls unexposed, sick), 2020 Bank (Phenytoin) (Mixed indications), 2017 Arkilo (Phenytoin), 2015 Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Phenytoin) (Controls unexposed, sick), 2013 Pennell (Phenytoin), 2012 Koch (Phenytoin), 1996 70.250.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-5.05.72.5320.000Aydin (Phenytoin) (Controls unexposed, sick), 2020Bank (Phenytoin) (Mixed indications), 2017Arkilo (Phenytoin), 2015Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014Artama (Phenytoin) (Controls unexposed, sick), 2013Pennell (Phenytoin), 2012Koch (Phenytoin), 1996

Asymetry test p-value = 0.4426 (by Egger's regression)

slope=0.2343 (0.6970); intercept=0.5585 (0.6702); t=0.8333; p=0.4426

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 9187, 9188, 9275, 9276, 9192

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.80[0.89; 8.89]64,006440%NAKilic (Phenytoin) (Controls unexposed NOS) (Mixed indications), 2014 Artama (Phenytoin) (Controls unexposed, disease free), 2013 Koch (Phenytoin), 1996 3 unexposed, sick controlsunexposed, sick controls 1.75[0.49; 6.21]472320%NAAydin (Phenytoin) (Controls unexposed, sick), 2020 Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Phenytoin) (Controls unexposed, sick), 2013 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.81[0.79; 4.16]109950%NAAydin (Phenytoin) (Controls exposed to Lamotrigine, sick), 2020 Bank (Phenytoin) (Mixed indications), 2017 Arkilo (Phenytoin), 2015 Kilic (Phenytoin) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Artama (Phenytoin) (Controls exposed to Lamotrigine, sick), 2013 Pennell (Phenytoin), 2012 60.510.01.0